

Supplementary Table 1

	Never Smoker	Current smoker	Ex-smoker at baseline	Ex: < 1 year	Ex : 1-2 years	Ex: 2-3 years	Ex: 3-5 years	Ex > 5 years
<b>All cancers</b>								
Events	463	1047	219	155	77	61	82	79
Crude Incidence*	5.15	8.06	6.87	10.18	7.42	7.62	7.08	6.08
(95% CI)	(4.71 – 4.65)	(7.58 – 8.56)	(6.02 – 7.84)	(8.70 – 11.92)	(5.94 – 9.28)	(5.93 – 9.79)	(5.70 – 8.79)	(4.88 – 7.58)
Adjusted+ IRR	1.00	1.28	1.09	1.66	1.24	1.27	1.20	1.01
(95% CI)		(1.10,1.49)	(0.92, 1.28)	(1.37,2.02)	(0.97,1.60)	(0.97,1.68)	(0.94,1.52)	(0.80,1.29)
<b>Lung cancers</b>								
Events	7	163	26	27	11	9	16	12
Crude Incidence*	0.08	1.25	0.82	1.77	1.06	1.12	1.38	0.92
(95% CI)	(0.04 – 1.16)	(1.08 – 1.46)	(0.56 – 1.20)	(1.22 – 2.59)	(0.59 – 1.91)	(0.58 – 2.16)	(0.85 – 2.26)	(0.52 – 1.63)
Adjusted+ IRR	1.00	13.13	7.79	19.08	11.37	11.66	13.85	8.69
(95% CI)		(5.83,29.55)	(3.37,17.99)	(8.10,44.95)	(4.32,29.92)	(4.29,31.68)	(5.62,34.15)	(3.40,22.18)
<b>Smoking related cancer excluding lung</b>								
Events	104	296	78	51	22	14	28	29
Crude Incidence*	1.16	2.28	2.45	3.35	2.12	1.75	2.42	2.23
(95% CI)	(0.96 – 1.40)	(2.03 – 2.55)	(1.96 – 3.05)	(2.55 – 4.41)	(1.40 – 3.22)	(1.04 – 2.95)	(1.67 – 3.50)	(1.55 – 3.21)
Adjusted+ IRR	1.00	1.32	1.58	2.06	1.32	1.06	1.43	1.32
(95% CI)		(0.97,1.78)	(1.18, 2.14)	(1.42,2.99)	(0.82,2.12)	(0.60,1.88)	(0.92,2.22)	(0.87,2.01)
<b>Smoking unrelated cancers</b>								
Events	352	588	115	77	44	38	38	38
Crude Incidence*	3.92	4.53	3.61	5.06	4.24	4.74	3.28	2.93
(95% CI)	(3.53 – 4.35)	(4.17 – 4.91)	(3.00 – 4.33)	(4.05 – 6.32)	(3.16 – 5.70)	(3.45 – 6.52)	(2.39 – 4.51)	(2.13 – 4.02)
Adjusted+ IRR	1.00	1.09	0.80	1.20	1.05	1.19	0.86	0.75
(95% CI)		(0.91,1.32)	(0.65 – 1.00)	(0.93,1.55)	(0.76,1.45)	(0.84,1.68)	(0.61,1.21)	(0.54,1.06)

\*per 1000 person-years of follow-up; CI confidence interval. + adjusted for baseline factors (gender, HIV transmission group, ethnicity, calendar year of baseline) and time varying factors (age [ $<40$ ,  $40\text{-}49$ ,  $>50$  year], body mass index (BMI;  $<18$ ,  $18\text{-}26$ ,  $27\text{-}30$ ,  $>30$  and unknown]), current CD4 cell count [ $<100$ , 100-199,200-299, 300-399, 400-499,  $\geq 500$ , unknown], current HIV-Viral load (HIV-VL;  $<50$ ,  $50\text{-}1000$ ,  $>1000$ , unknown copies/ml]), age, body mass index (BMI), current CD4 cell count, current HIV-Viral load (HIV-VL), hepatitis B (positive HBsAG surface antigen test or presence of detectable HBV DNA) and C virus co-infection (positive HCV surface antibody test), AIDS-diagnosis (excluding cancers), cardiovascular disease (CVD, including myocardial infarction, stroke and invasive cardiovascular procedures), diabetes (diagnosis, receiving diabetes medication), cART use (using  $\geq 1$  protease inhibitor [PI] or  $\geq 1$  non-nucleoside reverse transcriptase inhibitor [NNRTI]), and duration of smoking after enrolment in the D:A:D Study (years).